JBC Transcription and Nuclear Factor Monoclonals

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fan, F.
Right arrow Articles by Macnab, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fan, F.
Right arrow Articles by Macnab, R. M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Volume 271, Number 50, Issue of December 13, 1996 pp. 31981-31988
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Enzymatic Characterization of FliI
AN ATPase INVOLVED IN FLAGELLAR ASSEMBLY IN SALMONELLA TYPHIMURIUM*

(Received for publication, August 6, 1996, and in revised form, September 27, 1996)

Fan Fan and Robert M. Macnab

From the Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut 06520-8114

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
Acknowledgments
REFERENCES


ABSTRACT

FliI is a protein needed for flagellar assembly in Salmonella typhimurium. It shows sequence similarity to the catalytic beta subunit of the F0F1-ATPase and is even more closely related to putative ATPases in Type III bacterial secretory pathways. A His-tagged version of FliI, which was fully functional in complementation tests, was purified to homogeneity. It had an ATPase activity of 0.16 s-1 at 25 °C and pH 7, and a Km for ATP of 0.3 mM; Mg2+ was required. The activity was not affected by inhibitors of the F-, V- or P-type ATPases, or inhibitors of the Type I or Type II bacterial secretory pathways. Mutations K188I and Y363S decreased the ATPase activity about 100-fold, increased the Km about 10-fold, blocked flagellar assembly, and were dominant. Other FliI mutations that disrupted flagellar protein export were found near the N terminus; they permitted essentially wild-type ATPase activity, were not dominant, and showed a dosage-dependent phenotype. We propose that FliI has a C-terminal ATPase domain and an N-terminal domain that interacts with other components in the flagellum-specific export apparatus.


INTRODUCTION

The flagellum of Salmonella typhimurium and many other bacteria consists of a long helical filament, a short hook, and a basal body with a central rod and several rings (see Ref. 1 for a review). Only two of the structural components are exported by the general secretory pathway, which involves processing of an N-terminal signal peptide (2, 3); these two proteins, FlgI and FlgH, are the subunits of the outer-membrane and periplasmic rings of the basal body. All of the other external proteins are exported by a flagellum-specific pathway. These proteins (the subunits of the rod, hook, hook cap, hook-filament junction, filament, and filament cap) are thought to travel through a hollow channel in the nascent structure (4, 5) and assemble at its distal end (6, 7). The flagellar export apparatus is presumed to be at the base of the flagellum and involves at least three protein components, one of them being FliI (8).

Three classes of bacterial protein secretory pathways have been described (9). The Type I pathway (10), exemplified by the hemolysin secretion pathway of Escherichia coli, is signal peptide-independent; one of its components contains an ATP-binding cassette (ABC)1 and is called an ABC transporter or traffic ATPase. The ATPase activities of two such transporters, HlyB from E. coli and PrtD from Erwinia, have been described (11, 12). The Type II or general secretory pathway is signal sequence-dependent and proceeds in two stages: from cytoplasm to periplasm, and from periplasm to the external medium (13). The first step employs SecA as the ATPase that catalyzes pre-protein insertion and translocation. The most extensively studied Type II secretion system is that of pullulanase in Klebsiella oxytoca. PulE and its homologs contain a consensus ATP-binding site and have been termed traffic ATPases (14).

A third type of secretory pathway, Type III, has recently been identified in a variety of animal and plant pathogenic bacteria (1, 9, 15). This pathway is signal peptide-independent and involves many protein components. Type III secretory systems have several components homologous to proteins implicated in flagellar protein export (1, 15). Thus, although virulence protein secretion and flagellar protein export have different end results (host targeting versus organelle assembly), they are clearly related.

The flagellar protein export system and the Type III secretion systems all contain a putative ATPase component, which in the case of the flagellar system is FliI. Surprisingly, FliI and its homologs show similarity to the catalytic beta  subunit of the proton-translocating F0F1-ATPase (8).

Dreyfus et al. (16) demonstrated ATP binding by S. typhimurium FliI but failed to detect ATP hydrolysis. Since then, ATPase activity has been demonstrated for glutathione S-transferase fusions of the S. typhimurium Type III secretion component InvC (17) and FliI (18). In this study, we have purified a His-tagged version of FliI and characterized its ATPase activity in detail. We have also examined the effects of selected mutations on ATPase activity and on flagellation and motility.


EXPERIMENTAL PROCEDURES

Bacterial Strains

S. typhimurium SJW1103 is wild-type for motility and chemotaxis (19); MY644 is a temperature-sensitive (ts) fliI mutant (20); SJW2702 is a nonflagellate fliI null mutant (21). E. coli XL1-Blue (Stratagene, La Jolla, CA) was used as the recipient in cloning experiments, and BL21(DE3)pLysS (22) was used for overproduction of FliI.

Chemicals and Enzymes

Primers for PCR amplification and sequencing were synthesized using a model 392 DNA/RNA synthesizer (Applied Biosystems, Foster City, CA). Chemicals and enzymes were obtained from the following sources: Ampli-Taq DNA polymerase (Perkin-Elmer); Ni-NTA-agarose resin (Qiagen, Chatsworth, CA); ATP, ADP, GTP, ITP, CTP, phosphoenolpyruvate, malachite green, and ammonium molybdate (Sigma); NADH, pyruvate kinase, and lactate dehydrogenase (Boehringer Mannheim); bafilomycin A1, aurovertin B, and AMP-PNP (Calbiochem). All other chemicals were of at least reagent grade. Molar extinction coefficients (epsilon ) for the common nucleotides were taken from Ref. 23. Other epsilon  values used were: ITP, epsilon 249 = 12,200; bafilomycin A1, epsilon 245 = 25,000 (in methanol); aurovertin B, epsilon 372 = 34,400; vanadate, epsilon 268 = 3,630.

DNA Techniques and Plasmid Constructions

Recombinant DNA techniques were carried out by standard protocols (24). DNA sequencing by the dideoxynucleotide method (25) used Sequenase enzyme (U. S. Biochemical Corp.). Direct sequencing of PCR products was performed by a modified snap-cooling procedure (26).

Plasmids used are listed in Table I. The expression vector pET19b (Novagen Inc., Madison, WI) has a T7lac promoter-operator region and an optimal ribosome binding sequence (27), followed by DNA encoding 10 histidine residues and a linker region containing a cleavage site for enterokinase. pET-FLAG-19b was made in this study by changing the sequence GHI in the linker region to DYK to match the sequence of the octapeptide FLAG epitope tag (28).

Table I.

Plasmids used in this study


Plasmid Vectora FliI product Reference

pET-FLAG-19b pET19b Not applicable This work
pIK2101 pET11a Wild-type 16
pIFF600 pET22b Wild-type This work
pIFF200/pIFF700 pET/pTrc His-tagged wild-type This work
pIFF201 pET His-tagged C52T This work
pIFF203/pIFF703 pET/pTrc His-tagged L12Pb This work
pIFF204 pET His-tagged L12Pb This work
pIFF205/pIFF705 pET/pTrc His-tagged R7C/L12P This work
pIFF206/pIFF706 pET/pTrc His-tagged K188I This work
pIFF207/pIFF707 pET/pTrc His-tagged K188E This work
pIFF209/pIFF709 pET/pTrc His-tagged Y363S This work

a  pET, pET-FLAG-19b (see "Experimental Procedures"); pTrc, pTrc99A.
b  pIFF203 and pIFF703 carry the fliI allele from strain MY644, where the mutation L12P was identified; pIFF204 carries the fliI allele where the mutation L12P was introduced into the wild-type gene (see "Experimental Procedures").

Plasmid pIK2101 contains an Eco47III fragment of S. typhimurium DNA that encodes the entire fliI gene (16). PCR was used to create NdeI and BamHI sites at the 5' and 3' ends of fliI, respectively, by amplifying fliI using primers NdeI-FliIa (complementary to the vector sequence and the 5' end of fliI) and FliI-BamHIb (complementary to the vector sequence and the 3' end of fliI). The amplified fragment was digested with NdeI and BamHI and cloned into vector pET-FLAG-19b, yielding plasmid pIFF200, encoding a His-tagged but otherwise wild-type FliI, or vector pET22b, yielding plasmid pIFF600, encoding an untagged wild-type FliI.

Chromosomal DNA from fliI mutant strain MY644 was prepared following the protocol of Woo et al. (29), and the mutant fliI allele was amplified using primers NdeI-FliIa and FliI-BamHIb. The fragment was then cloned into pET-FLAG-19b to give plasmid pIFF203.

The FliI mutations C52T, L12P, and R7C/L12P were made by PCR-directed mutagenesis (30). To generate the two mutagenic fragments from plasmid pIFF200, the two primary PCR reactions used either a T7 promoter a-strand primer and the b-strand mutamer, or the a-strand mutamer and FliI-BamHIb. These two fragments were allowed to anneal and extend and the T7 promoter primer and FliI-BamHIb were used to amplify the extended fragment. The mutagenic site was cloned as a 0.5-kilobase pair NdeI-HpaI fragment to replace the corresponding wild-type sequence in plasmid pIFF200, yielding plasmids pIFF201 (FliI C52T) and pIFF204 (FliI L12P). In one clone we found a second mutation causing the amino acid change R7C; the resulting plasmid was pIFF205 (FliI R7C/L12P).

The mutations FliI K188I, K188E and Y363S had been made previously (16). The K188I and K188E mutagenic sites were cloned as 0.8-kilobase pair MluI-PstI fragments, replacing the corresponding wild-type sequence in pIFF200, and yielding plasmids pIFF206 and pIFF207. Similarly, a 0.5-kilobase pair PvuI-PstI fragment in pIFF200 was replaced by the same fragment containing the Y363S mutagenic site, yielding plasmid pIFF209. All mutations were confirmed by sequencing.

The NcoI-BamHI fragments containing the His-tagged wild-type or mutant fliI alleles from the pET-FLAG-19b-based plasmids were also cloned into pTrc99A under the control of the trc promoter (31).

Complementation and Dominance Analysis

S. typhimurium was transformed by electroporation (E. coli Pulser, Bio-Rad). Plasmids were used to transform SJW2702 (fliI null) for complementation, or SJW1103 (wild-type) and MY644 (fliIts) for dominance analysis. Semisolid tryptone agar (0.35%) plates containing ampicillin (50 µg/ml) were used to examine the motility of transformed cells at 30 °C or 42 °C. Extent of flagellation and motility were examined by high intensity dark-field light microscopy (32).

Overproduction and Purification of FliI

E. coli BL21(DE3)pLysS was transformed with pET-FLAG-19b-based plasmids containing fliI alleles. Cells were grown overnight at 30 °C in 10 ml of Luria medium containing 50 µg/ml ampicillin, placed in 1 liter of the same medium, and grown at 25 °C to an optical density at 600 nm of 0.5. IPTG was added to 0.2 mM, and growth was continued for 10 h. The cells were harvested (10,000 × g, 15 min) and the pellets resuspended in 30 ml binding buffer (20 mM Tris-Cl, pH 8, 500 mM NaCl, 5 mM imidazole, 1 mM beta -mercaptoethanol). The cells were disrupted by passage three times through a French press (SLM Instruments, Urbana, IL) at 4000 p.s.i. The lysate was centrifuged (17,000 × g, 40 min) to pellet unlysed cells and inclusion bodies. The supernatant was centrifuged at 150,000 × g for 2.5 h and the pellet discarded. The soluble fraction was loaded onto a column containing 5-10 ml of Ni-NTA-agarose pre-equilibrated with binding buffer at a flow rate of 10-15 ml/h. The column was washed with 50 ml of binding buffer and then with 50 ml of binding buffer plus 25 mM imidazole. FliI was eluted with a gradient of 25-250 mM imidazole in binding buffer. Fractions containing FliI were identified by SDS-PAGE, pooled, and concentrated to 5 ml (YM-30 membrane, Stirred Cell 8050, Amicon, Beverly, MA). After overnight dialysis (Spectra/Por 1 membrane) against 4 liters of 20 mM Tris-Cl pH 8, 0.25 mM EDTA, 1 mM beta -mercaptoethanol (with 1 change), FliI was further concentrated to about 0.5 ml (Centriprep-30 and Centricon-30 concentrators, Amicon). Protein concentration was measured spectrophotometrically by intrinsic absorbance at 280 nm or by the Bradford dye binding assay using bovine serum albumin as a standard (Bio-Rad). All stages of the purification were performed at 4 °C.

FPLC gel filtration chromatography employed a Superdex HR200 10/30 column (Pharmacia Biotech Inc.) and binding buffer.

ATPase Activity Measurements

Two methods of assaying ATPase activity were used. The first was a malachite green assay (33), with minor modifications from the protocol described by Eichelberg et al. (17). ATPase activity was also measured in an enzyme-coupled assay (34) that uses an ATP-regenerating system coupled to the oxidation of NADH.

ATPase activity in situ was performed by electrophoresing 30 µg of purified FliI in each of two lanes of a 1% agarose native gel, with a running buffer consisting of 20 mM Tris-Cl, 250 mM glycine, pH 8.8. The two lanes of the gel were then cut apart, and one was stained with Coomassie Brilliant Blue. The other lane was incubated for 30 min with the running buffer plus 5 mM ATP and 5 mM Mg2+, and the released Pi was then stained for 20 min with malachite green reagent.

Circular Dichroism

Far-UV CD spectra were collected on a Model 62DS spectrometer (AVIV, Lakewood, NJ). Purified FliI (~10 mg/ml) in buffer was diluted with 1 mM beta -mercaptoethanol to about 0.5 mg/ml. Spectra were collected at 1-nm intervals with an average of 5 s/point; each spectrum was the average of three scans. To estimate the secondary structural content, spectra were analyzed by convex constraint analysis and the LINCOMB program (35). Thermal denaturation was performed by heating the sample while monitoring the ellipticity at 220 nm (1 °C step size, 2-min equilibration time, 30-s acquisition time). Complete spectra were taken at the beginning (4 °C) and ending (98 °C) temperatures.


RESULTS

Overproduction and Properties of the FliI Protein

pIFF200 (encoding His-tagged wild-type FliI) or pIFF600 (encoding untagged wild-type FliI) was used to transform SJW2702, a nonflagellate fliI null mutant. Both transformants swarmed equally well (Fig. 1) and were comparable to untransformed wild-type strain SJW1103, establishing that the His-tagged FliI protein was fully functional.


Fig. 1. Complementation analysis of wild-type and mutant fliI alleles. SJW2702 (fliI null) was transformed with various pET-based plasmids. pIFF600 (top row, left) contained an intact wild-type fliI allele, whereas the other plasmids had fliI alleles with an N-terminal His tag: wild-type (plasmid pIFF200, top row, right); C52T (plasmid pIFF201), L12P (plasmid pIFF203), and R7C/L12P (pIFF205) (middle row, left to right); K188I (pIFF206), K188E (pIFF207), Y363S (pIFF209), vector alone (pET-FLAG-19b) (bottom row, left to right). Cells were spotted on soft tryptone agar plates containing ampicillin and incubated at 30 °C for 7 h.
[View Larger Version of this Image (117K GIF file)]


His-tagged FliI was overproduced under the control of the T7 promoter using pIFF200 and E. coli BL21(DE3)pLysS. Following induction by IPTG, the amount of His-tagged FliI increased greatly, comprising more than half of the total cellular protein (Fig. 2, cf. lanes 1 and 2). Most of it formed inclusion bodies, which could be removed by medium speed centrifugation (lane 3). Following high speed centrifugation of the supernatant to remove membrane fragments, about 5% remained in the soluble fraction (lane 4), which could then be purified to homogeneity on a nickel column (lane 6) and concentrated, yielding up to 10 mg from 1 liter of culture. Immunoblotting using anti-FLAG antibody or anti-FliI antibody (16) confirmed the identity of the protein. The concentrated protein was soluble to at least 30 mg/ml in buffer and was routinely stored at 4 °C at >10 mg/ml.


Fig. 2. SDS-PAGE (12.5%) of samples during purification of His-tagged FliI. Lane 1, total protein of uninduced cells transformed with pIFF200. Lane 2, total cell protein following induction with IPTG. Lane 3, pellet of French press cell lysate, containing the FliI inclusion bodies. Lane 4, soluble fraction following high speed spin (load to Ni-NTA column). Lane 5, flow-through from Ni-NTA column. Lane 6, final pool of purified FliI eluted from Ni-NTA column. The arrow indicates the position of the His-tagged FliI. Molecular masses (in kilodaltons) of standards are shown on the left.
[View Larger Version of this Image (73K GIF file)]


FPLC gel filtration chromatography revealed a peak at 53 kDa, corresponding to monomeric FliI; no well defined oligomeric forms of FliI were detected. In the absence of reducing agents, FliI formed dimers. Site-directed mutagenesis of the sole cysteine residue, Cys-52, abolished dimer formation but left FliI function intact (Fig. 1). We conclude that the dimerization has no physiological significance, and also that Cys-52 is solvent-exposed but is not essential for FliI function.

Spectral and Thermal Properties of FliI

The far-UV CD spectrum of His-tagged FliI is shown in Fig. 3a. The high negative molar ellipticity around 220 nm and 208 nm indicates that at 4 °C FliI contains considerable amounts of secondary structure (~22 mol % alpha  helix and, less reliably, 34 mol % beta  structure). This is in agreement with predictions of secondary structure based on the sequence and with the known structure of the catalytic beta  subunit of the F1-ATPase (36). The melting curve of FliI showed a cooperative transition of a putative subdomain, with a Tm value of 51 °C (Fig. 3b), but a stable core structure remained even at 98 °C (Fig. 3a).


Fig. 3. Circular dichroism measurement of His-tagged FliI. a, CD spectra (solid line) of wild-type FliI at 4 °C and 98 °C, and LINCOMB fit to the 4 °C data (dashed line). b, temperature melting curve of His-tagged FliI. The Tm value for this subdomain was estimated to be 51 °C.
[View Larger Version of this Image (11K GIF file)]


ATPase Activity of FliI

Purified His-tagged FliI was shown to have ATPase activity by two independent assays (see "Experimental Procedures"). Since the results obtained by the two assays were essentially the same, we routinely employed the malachite green assay because of its simplicity.

The FliI protein was essentially pure, as judged by Coomassie staining. To exclude the possibility that there might be small amounts of highly reactive ATPase contaminants, we assayed the activity of purified FliI in situ in native gels. The only major band identified by the ATPase assay co-migrated with the only major band identified by Coomassie staining (Fig. 4). Mutant versions of FliI involving a loss of positive charge (FliI R7C/L12P and FliI K188I) ran slightly faster than wild-type FliI, confirming the presence of the mutation.


Fig. 4. Assay of FliI ATPase activity in situ in an agarose native gel system. a, protein stained by Coomassie Brilliant Blue. b, ATPase activity assayed by staining using the malachite green method.
[View Larger Version of this Image (43K GIF file)]


ATP was the best substrate for the reaction (Fig. 5a). GTP and ITP produced much lower reaction rates, and CTP essentially did not serve as a substrate at all. The reaction followed Michaelis-Menten kinetics with a Vmax at 25 °C of 0.2 µmol of ATP hydrolyzed/min/mg of protein (corresponding to a kcat of 0.16 s-1) and a Km for ATP of about 0.3 mM (Fig. 5b). ATP hydrolysis required a divalent cation (Fig. 5c). When Mg2+ was varied from 0.06 to 10 mM, the data fit well to the Michaelis-Menten equation and yielded a Km for Mg2+ of about 1.1 mM. Mn2+ could substitute, but reaction rates were reduced by about 70%. Zn2+, Co2+, and Ni2+ functioned almost as well as Mg2+ at lower concentrations but were inhibitory above 2.5 mM. No ATP hydrolysis was detected when Ca2+ was used. Maximal activity of FliI was observed around pH 8 (Fig. 5d), where it was about 2-fold higher than at the standard assay pH of 7. Activity decreased abruptly at acidic pH and above pH 9.5. At acidic pH, denaturation and aggregation occurred, but protonation or deprotonation of critical residues may also have affected activity.


Fig. 5. ATPase activity of FliI, measured at 25 °C using the malachite green method. Rates were corrected for the non-enzymatic release of Pi from controls without FliI. a, nucleotide specificity, at 5 mM Mg2+ and pH 7. b, double-reciprocal plot for ATP hydrolysis. c, divalent metal ion specificity, at 5 mM ATP and pH 7. d, pH dependence, at 5 mM ATP and 5 mM Mg2+; buffers (50 mM) of pH 5.5-6.5, 7.0-8.0, 8.5-9.5, and 9.5-11 were made from 0.5 M MES, HEPES, AMPSO, and CAPS stock, respectively. e, competitive inhibition by ADP, at 5 mM Mg2+ and pH 7. The data were analyzed by the COMP program (70) to yield the value of Ki.
[View Larger Version of this Image (28K GIF file)]


ADP was a competitive inhibitor, with a Ki of 0.26 mM (Fig. 5e). We tested inhibitors of the P-, V-, and F-type ion-translocating ATPases, of the SecA component of the general secretory pathway, and of the ATPase component of the Type I secretory pathway (Table II); none of these compounds had an inhibitory effect on FliI.

Table II.

Effect of ATPase inhibitors on FliI ATPase activity

ATPase activity was measured using the malachite green assay (see "Experimental Procedures"). Stock solutions of bafilomycin A1, aurovertin B, and DCCD were prepared in dimethylsulfoxide, methanol, and ethanol, respectively. The final solvent concentration in the sample assay mixture (and in controls without the compound) was less than 1%. FliI was preincubated with the compounds for 10 min before addition of ATP to initiate the reaction. The effect of DCCD was also measured at pH 6.5, following the procedure of Satre et al. (64). In control experiments, vanadate and DCCD were shown to inhibit the P-type plasma membrane ATPase of N. crassa by more than 80%.
Compound FliI ATPase activity Specific fora Reference

%
None 100
Vanadate (0.4 mM) 130 P, I 11, 12, 65
Bafilomycin A1 (16 µM) 105 V 66
KNO3 (10 mM) 93 V 67
NaN3 (10 mM) 98 F, A 68, 69
Aurovertin B (60 µM) 96 F 57
AMP-PNP (1 mM) 94 F, V 58, 67
DCCD (10 µM to 5 mM) 120-200 P, V, F 54, 64

a  P, phosphorylation type ATPase (formerly known as E1E2 type); V, vacuolar type ATPase; F, F0F1 type ATPase; A, SecA component of the general (Type II) secretory pathway of bacteria; I, ATPase of the Type I bacterial secretory pathway.

Characterization of fliI Mutant Strains and FliI Mutant Proteins

MY644 is a temperature-sensitive fliI mutant (8, 20). At the permissive temperature of 30 °C, MY644 cells swarmed, although not as well as wild-type cells (Fig. 6a). In liquid medium, they were significantly less motile than wild-type cells; few cells had more than one flagellar filament long enough to be visible by high intensity dark-field microscopy (32), and even these failed to form a flagellar bundle. At the restrictive temperature of 42 °C, MY644 cells had almost no swarming ability (Fig. 6b), whereas wild-type cells swarmed even better than at 30 °C, presumably because of a combination of higher torque generation, faster growth, and softer agar. The fliI allele in MY644 was found to cause the mutation L12P near the N terminus. When SJW2702 (fliI null) was transformed with the pET-based plasmid pIFF203 bearing the mutant allele from MY644, swarming was similar to that of MY644 and showed the same temperature-sensitive phenotype (Fig. 6). We also made the mutation L12P in the wild-type fliI allele; SJW2702 transformed with the resulting plasmid (pIFF204) behaved identically to cells transformed with pIFF203, establishing that the L12P mutation alone was responsible. Placing the L12P allele in the pTrc99A vector to give plasmid pIFF703 improved swarming at both temperatures (Fig. 6), indicating a dosage effect (see below). In liquid medium, cells transformed with pIFF703 and grown at the permissive temperature were seen to be well flagellated (5-8 flagella/cell) and highly motile. A double mutation at the N terminus, R7C/L12P, had a more severe effect on motility than did the L12P mutation alone (Fig. 1). Flagellation, motility, and swarming were improved when the allele was expressed from the pTrc99A-based plasmid pIFF705. The temperature sensitivity associated with the L12P mutation persisted in the double mutant.


Fig. 6. Temperature sensitivity and dosage effect associated with the L12P mutation in FliI. Cells were spotted on soft tryptone agar plates and incubated at 30 °C (a) or 42 °C (b) for 6 h. Top left, strain SJW1103 (wild-type). Top right, MY644 (FliI L12P). Bottom left, SJW2702 (fliI null) transformed with the pET-based plasmid pIFF203 (FliI L12P). Bottom right, SJW2702 transformed with the pTrc99A-based plasmid pIFF703 (FliI L12P).
[View Larger Version of this Image (80K GIF file)]


His-tagged versions of these mutant proteins were purified. FliI L12P was found to have an ATPase activity comparable to that of wild-type FliI, and FliI R7C/L12P had an activity higher than that of wild-type FliI (Table III). Thus, these residues at the N terminus of the protein are not needed for catalytic activity. This region of the protein is predicted to form an alpha  helix. CD spectra of the mutant proteins showed small but reproducible decreases (of 5% and 8%, respectively) in the ratio of ellipticity at 222 nm versus 208 nm and a slight blue shift of the minimum at 208 nm, both of these changes indicating that the mutant proteins have reduced helical contents. However, they showed the same subdomain melting temperature (51 °C) as the wild-type protein, indicating that this is not a property of the N terminus.

Table III.

Kinetic constants of wild-type and mutant FliI

ATPase activity was measured using the malachite green assay as described under "Experimental Procedures." ATP concentrations were varied from 0.17 to 5 mM. Data were fit to the Michaelis-Menten equation to obtain Km and V, using the HYPER program (70). Standard errors were less than 10% except for those of K188I and Y363S FliI, which were 20-30%.
FliI Km V

mM µmol/min/mg
Wild-type 0.26 0.20
L12P 0.25 0.1
R7C/L12P 0.24 0.48
K188I 1 0.002
Y363S 4 0.004

Site-directed mutations (K188I, K188E, D272N, and Y363S) had been made previously at positions that were predicted to be catalytically important based on homology with the beta  subunit of the F1-ATPase. These mutant alleles had shown very poor complemention of an E. coli fliI mutant (16). We created His-tagged versions of three of these alleles (K188I, K188E, and Y363S). The corresponding plasmids (pIFF206, 207, and 209) failed to complement SJW2702 (Fig. 1). When the alleles were overexpressed from pTrc99A-based plasmids (pIFF706, 707, and 709) the K188I and K188E mutations still gave no complementation, and in liquid medium less than 1% of the cells gave any indication of motility; even on these, there were no flagellar filaments long enough to be seen in the microscope. With the Y363S mutation, a small percentage of the cells were slightly motile, but again no filaments could be seen.

The activities of FliI K188I and Y363S were about 100-fold lower than that of wild-type FliI, and the Km values for ATP were about 10-fold higher (Table III). The mutant proteins had essentially the same CD spectra as wild-type FliI, but the melting temperature was reduced by 5 C°, indicating that these residues probably lay within the subdomain that was undergoing denaturation. FliI K188E gave at least a 100-fold lower yield, and we were unable to characterize its enzymatic activity.

Dosage and Dominance Effects

The wild-type and mutant fliI alleles in pTrc99A or pET-FLAG-19b were used to test for dosage or dominance effects over the wild-type chromosomal allele of SJW1103 (Fig. 7). Immunoblotting (using either anti-FliI or anti-FLAG antibody) established that, for growth in Luria medium, the amount of FliI with the pTrc99A-based plasmids was about 50,000 molecules/cell, whereas with the pET-based plasmids in hosts lacking the T7 polymerase, it was below the detection limit of approximately 500 molecules/cell.


Fig. 7. Swarm plates illustrating dosage and dominance effects associated with wild-type and mutant versions of FliI. SJW1103 (wild-type) was transformed with plasmids derived from the pTrc99A vector. The plasmids were (from left to right) as follows. Top row, pIFF700 (wild-type fliI), pTrc99A vector; middle row, pIFF703 (FliI L12P), pIFF705 (FliI R7C/L12P); bottom row, pIFF706 (FliI K188I), pIFF707 (FliI K188E), pIFF709 (FliI Y363S). Photograph was taken after 6 h at 30 °C.
[View Larger Version of this Image (128K GIF file)]


Expression of His-tagged wild-type FliI from a pTrc99A-based plasmid neither enhanced nor inhibited swarming of wild-type SJW1103 cells, and neither FliI L12P nor R7C/L12P had any dominant effect over the wild-type protein (Fig. 7). In contrast, all three catalytic mutant alleles were dominant, the effect being more pronounced with FliI K188I and K188E than with FliI Y363S. In liquid medium, FliI K188I and K188E were seen to greatly reduce the motility of SJW1103 (about 10% of the cells were poorly motile, and their filaments were too short to be seen). Cells making FliI Y363S were fairly motile, and in the dark-field microscope, a few filaments, which sometimes formed a bundle, could be seen on some cells. None of the mutant alleles showed dominance when they were being expressed at low levels from the pET vector, indicating that the effect was dosage-dependent.

Analysis was also performed using MY644 (FliI L12P) as host. With both the pTrc99A-based and the pET-based plasmids, the wild-type fliI allele was dominant. Synthesis of FliI L12P from the pTrc99A-based plasmid pIFF703 (and to a lesser degree from the pET-based plasmid pIFF203) improved the swarming of MY644, consistent with the phenotype of SJW2702 transformed with these plasmids (Fig. 6a). Thus, higher levels of FliI L12P improved function. The same was true of the R7C/L12P double mutant allele, although the effect was not as pronounced. Among the catalytic mutant alleles, both K188I and K188E showed dominance with both vector systems, whereas the Y363S allele showed it only with the pTrc99A-based vector.


DISCUSSION

The flagellar morphogenetic pathway of S. typhimurium has been studied extensively (1, 37). The process by which many flagellar proteins are translocated from the cytosol to the distal end of the growing structure, however, is not understood. Several proteins are believed to be implicated (8). Among these is FliI, which is especially interesting because of its similarity to the catalytic beta  subunit of the F1-ATPase and to homologous proteins in Type III bacterial secretion systems; FliI has been identified in a variety of diverse bacterial species in addition to S. typhimurium (8) and E. coli,2 including the Gram-positive bacterium Bacillus subtilis (38), the spirochete Borrelia burgdorferi (39), and the photosynthetic bacterium Rhodobacter sphaeroides (40, 41).

A previous study, using FliI purified from inclusion bodies, failed to detect any ATPase activity (16), perhaps because the protein was not fully refolded into its native state. Using a His-tagged version, we have now been able to purify FliI to homogeneity from the soluble fraction in sufficient quantities for detailed enzymatic analysis. This His-tagged FliI clearly has ATPase activity (Fig. 4); activity has also been demonstrated with a glutathione S-transferase fusion version of FliI (18) and with partially purified untagged FliI.3

The His-tagged FliI we have studied is fully functional in complementation tests (Fig. 1), giving confidence that its enzymatic and other properties reflect those of the untagged protein. It was active as the monomer and had a simple non-cooperative ATPase activity of 0.2 µmol/min/mg (0.16 s-1) in an assay mixture containing 5 mM ATP and 5 mM Mg2+ at pH 7 (Fig. 4), conditions that are close to those in vivo (pH around 7.6 and ATP around 3 mM; Refs. 42 and 43). This ATPase activity is comparable to those seen for ATPases of other protein export and secretory systems (11, 12, 44, 45), including InvC, the FliI homolog in the S. typhimurium virulence secretion system (17). It is much lower than the multisite (steady-state) activity of F1-ATPase (~50 s-1), but is 100-fold higher than the unisite activity (~10-3 s-1) (46).

We have identified several residues that are important catalytically (Table III). Lys-188 of FliI is within the motif A (Gly-X4-Gly-Lys), where X represents any amino acid), which is found in many ATPases (47) and lies within the nucleotide binding site (36). The mutation K188I decreased ATPase activity by 100-fold, establishing that Lys-188 is an essential residue for catalysis, as is the equivalent residue in other ATPases (12, 48, 49, 50). Tyr-331 in the E. coli F1 beta  subunit is a conserved amino acid residue among the known beta  subunits (51), and modification by 2-azido-ATP or other affinity labeling reagents results in inhibition of catalysis (46, 52). In mitochondrial beta , the corresponding residue has been shown to be in the nucleotide binding site and to have a hydrophobic interaction with the adenine ring of ATP (36). The substitution Y331S (but not Y331F) in E. coli beta  increases the Km value by 30-fold and decreases the activity by 10-fold, suggesting that this residue is important for ATP binding but is not directly involved in catalysis (53). We found similar effects with the substitution Y363S at the equivalent position in FliI, further indicating that FliI and the F1 beta  subunit are structurally related.

FliI has sequence similarity to the catalytic subunits of the F1, vacuolar, and archaebacterial ATPases (8). To see whether this might be reflected at the mechanistic level, we tested various known inhibitors of ATPases (see Ref. 54 for a review) (Table II). Inhibitors of P(hosphorylation)-type ATPases had no effect on FliI activity, which is not surprising since these ATPases employ a very different reaction mechanism. Inhibitors of F-type or V-type ATPases also had no effect on FliI. Interestingly, although sodium azide strongly inhibits the multisite ATPase activity of F1, it does not affect its unisite activity (46, 55); FliI is active as monomer and so might be expected to more closely resemble the unisite activity. Aurovertin B inhibits F1-ATPase by binding to Arg-398 in the beta  subunit (56, 57); there is no corresponding Arg in FliI. AMP-PNP is a nonhydrolyzable ATP analog, which impairs the normal cooperativity of F1 (58); since no cooperativity was associated with FliI, AMP-PNP should at most act as a competitive inhibitor. We did not observe inhibition by AMP-PNP to at least 1 mM, indicating that its binding affinity must be quite low. DCCD also did not inhibit FliI. In fact, it caused a stimulation of activity, suggesting it may be inhibiting a feature of the protein that itself regulates ATPase activity.

The divalent cation specificity of FliI also showed significant differences from that of the F1-ATPase. At 5 mM ATP, Mg2+ was stimulatory up to at least 10 mM, whereas for the F1-ATPase, it is inhibitory above 2.5 mM; and Ca2+ could not support the activity of FliI, whereas it is almost as effective as Mg2+ for the F1-ATPase (46, 59).

We conclude from the inhibition studies and the metal ion dependence that, in spite of the similarities between FliI and F1 beta  at the sequence level, their reaction mechanisms are probably rather different. At least part of the difference may derive from the fact that FliI is reactive as monomer (although its state in vivo is not known) whereas beta  is part of a large, highly cooperative complex.

We imagine that, in the living cell, ATP hydrolysis by FliI is coupled to some other process, which entails physical interactions with one or more other flagellar proteins. We do not yet know what that process is. One possibility is the energization of the protein transport process; another is chaperone function. We favor the former possibility, since known chaperones with ATPase activity, such as DnaK, differ from FliI in several regards. They have extremely high affinity for ATP (typically in the submicromolar range, cf. 0.3 mM with FliI) (60, 61) and low reactivity (turnover numbers in the 10-3 s-1 range, cf. 0.16 s-1 for FliI) (62, 63). Also, they are considerably larger (~70 kDa, cf. 49 kDa for FliI).

The filament is by far the major substructure of the flagellum, consisting of about 20,000 flagellin subunits. There are typically about 5 flagella on a wild-type cell, and so about 100,000 flagellin subunits have to be assembled within a generation time (~75 min in Luria medium at 25 °C, the temperature at which ATPase activity was assayed). This corresponds to an assembly rate of about 22 s-1. If FliI is implicated in the process, and there are about 1000 FliI molecules/cell (8), this would require a kcat of at least 0.02 s-1, if one ATP has to be hydrolyzed per flagellin subunit exported and assembled. The observed kcat of 0.16 s-1 for purified FliI indicates that it is capable of performing the task.

An important next step will be to identify the components that interact with FliI and the part of FliI that is responsible for the interaction. In the latter regard, the differences between the properties of the catalytic mutations and the N-terminal mutations R7C and L12P are highly suggestive. The catalytic mutations cause not only the expected severe decrease in enzymatic activity but also dominance over wild-type FliI. This is what would be expected if the mutant proteins were still competent to interact with other flagellar components, because they would sequester these components but would be unable to perform the ATPase-linked function. Conversely, if the N-terminal mutations impair the interaction, they would be recessive and wild-type FliI could function unimpeded with the other flagellar components. Thus there is a strong prediction that at least some part of the N-terminal region of FliI is responsible for the interaction, a prediction that is reinforced by the fact that the corresponding sequence is lacking in F1 beta . FliI has a substantial N-terminal overhang with respect to beta , and credible similarity between the two sequences does not commence until around residue 110 of FliI (8). Mutations such as R7C or L12P at the N terminus might perturb the interaction between FliI and other flagellar proteins. It is interesting that the R7C/L12P double mutation reproducibly stimulated ATPase activity, suggesting that the N terminus may exert a regulatory effect on the catalytic mechanism (cf. the stimulatory effect of DCCD).

The fact that the L12P mutation has an adverse effect on filament assembly immediately upon shift to the restrictive temperature (rather than after times comparable to the generation time) suggests that the interaction may be a transient one and that FliI is probably not tightly and permanently locked into the flagellar structure (cf. discussion in Refs. 8 and 16). The dosage dependence effect of the various mutant FliI proteins further supports the idea that the interaction may be a transient one in which the free concentration is important.

We suggest that FliI functions as a two-domain protein, with an N-terminal domain engaged in some flagellum-specific process and a C-terminal domain, which is responsible for the ATPase activity that drives the process. Deletion analysis should allow definition of the boundary between these two predicted domains.


FOOTNOTES

*   This work has been supported by United States Public Health Service Grant AI12202. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
   To whom correspondence should be addressed. Tel.: 203-432-5590; Fax: 203-432-9782; E-mail: robert_macnab{at}qm.yale.edu.
1    The abbreviations used are: ABC, ATP-binding cassette; Ni-NTA, Ni-nitrilotriacetic acid; AMP-PNP, 5'-adenylyl imidodiphosphate; AMPSO, 3-[(1,1,-dimethyl-2-hydroxyethyl)amino]-2-hydroxypropanesulfonic acid; CAPS, 3-(cyclohexylamino)-1-propanesulfonic acid; DCCD, dicyclohexylcarbodiimide; IPTG, isopropyl-1-thio-beta -D-galactopyranoside; MES, 2-(N-morpholino)ethanesulfonic acid; PAGE, polyacrylamide gel electrophoresis; PCR, polymerase chain reaction.
2    M. Kihara and R. M. Macnab, unpublished data.
3    E. Silva-Herzog and G. Dreyfus, personal communication.

Acknowledgments

We acknowledge Lisa Postow for contributions to the analysis of metal ion specificity and to the characterization of N-terminal mutant versions of the FliI protein. We thank Eugenia Silva-Herzog and Georges Dreyfus (Universidad Nacional Autónoma de México) for exchange of information regarding their studies of FliI; Katrin Eichelberg and Jorge Galán (SUNY Stonybrook) for advice based on their experience with InvC; Kenneth Allen for the gift of plasma membrane ATPase and for advice concerning ATPase inhibitors; Richard Yu for assistance with FPLC analysis; Jenny Yang for assistance with the CD analysis; and May Kihara for technical support.


REFERENCES

  1. Macnab, R. M. (1996) in Escherichia coli and Salmonella: Cellular and Molecular Biology (Neidhardt, F. C., Curtiss, R., III, Ingraham, J. L., Lin, E. C. C., Low, K. B., Jr., Magasanik, B., Reznikoff, W. S., Riley, M., Schaechter, M., and Umbarger, H. E., eds), 2nd Ed., pp. 123-145, ASM Press, Washington, DC
  2. Jones, C. J., Homma, M., and Macnab, R. M. (1989) J. Bacteriol. 171, 3890-3900 [Abstract/Free Full Text]
  3. Schoenhals, G. J., and Macnab, R. M. (1996) J. Bacteriol. 178, 4200-4207 [Abstract/Free Full Text]
  4. Mimori, Y., Yamashita, I., Murata, K., Fujiyoshi, Y., Yonekura, K., Toyoshima, C., and Namba, K. (1995) J. Mol. Biol. 249, 69-87 [CrossRef][Medline] [Order article via Infotrieve]
  5. Morgan, D. G., Owen, C., Melanson, L. A., and DeRosier, D. J. (1995) J. Mol. Biol. 249, 88-110 [CrossRef][Medline] [Order article via Infotrieve]
  6. Emerson, S. U., Tokuyasu, K., and Simon, M. I. (1970) Science 169, 190-192 [Abstract/Free Full Text]
  7. Iino, T. (1969) J. Gen. Microbiol. 56, 227-239 [Medline] [Order article via Infotrieve]
  8. Vogler, A. P., Homma, M., Irikura, V. M., and Macnab, R. M. (1991) J. Bacteriol. 173, 3564-3572 [Abstract/Free Full Text]
  9. Salmond, G. P. C., and Reeves, P. J. (1993) Trends Biochem. Sci. 18, 7-12 [CrossRef][Medline] [Order article via Infotrieve]
  10. Fath, M. J., and Kolter, R. (1993) Microbiol. Rev. 57, 995-1017 [Abstract/Free Full Text]
  11. Koronakis, V., Hughes, C., and Koronakis, E. (1993) Mol. Microbiol. 8, 1163-1175 [CrossRef][Medline] [Order article via Infotrieve]
  12. Delepelaire, P. (1994) J. Biol. Chem. 269, 27952-27957 [Abstract/Free Full Text]
  13. Pugsley, A. P. (1993) Microbiol. Rev. 57, 50-108 [Abstract/Free Full Text]
  14. Possot, O., and Pugsley, A. P. (1994) Mol. Microbiol. 12, 287-299 [Medline] [Order article via Infotrieve]
  15. Galán, J. E. (1996) Mol. Microbiol. 20, 263-271 [CrossRef][Medline] [Order article via Infotrieve]
  16. Dreyfus, G., Williams, A. W., Kawagishi, I., and Macnab, R. M. (1993) J. Bacteriol. 175, 3131-3138 [Abstract/Free Full Text]
  17. Eichelberg, K., Ginocchio, C. C., and Galán, J. E. (1994) J. Bacteriol. 176, 4501-4510 [Abstract/Free Full Text]
  18. Williams, A. W. (1995) The Roles of FliI, FliK, and FlhB Proteins in the Export and Assembly of the Bacterial Flagellum. Ph.D. thesis, Yale University, New Haven, CT
  19. Yamaguchi, S., Fujita, H., Taira, T., Kutsukake, K., Homma, M., and Iino, T. (1984) J. Gen. Microbiol. 130, 3339-3342 [Medline] [Order article via Infotrieve]
  20. Jones, C. J., and Macnab, R. M. (1990) J. Bacteriol. 172, 1327-1339 [Abstract/Free Full Text]
  21. Kubori, T., Shimamoto, N., Yamaguchi, S., Namba, K., and Aizawa, S.-I. (1992) J. Mol. Biol. 226, 433-446 [CrossRef][Medline] [Order article via Infotrieve]
  22. Studier, F. W., and Moffatt, B. A. (1986) J. Mol. Biol. 189, 113-130 [CrossRef][Medline] [Order article via Infotrieve]
  23. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. (eds) (1990) Current Protocols in Molecular Biology, p. A.1.15, Greene Publishing Associates and Wiley-Interscience, New York
  24. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
  25. Sanger, F., Nicklen, S., and Coulson, A. R. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 5463-5467 [Abstract/Free Full Text]
  26. Kusukawa, N., Uemori, T., and Kato, L. (1990) BioTechniques 9, 66-72 [Medline] [Order article via Infotrieve]
  27. Dubendorff, J. W., and Studier, F. W. (1991) J. Mol. Biol. 219, 45-59 [CrossRef][Medline] [Order article via Infotrieve]
  28. Hopp, T. P., Prickett, K. S., Price, V. L., Libby, R. T., March, C. J., Cerretti, D. P., Urdal, D. L., and Conlon, P. J. (1988) Bio/Technology 6, 1204-1210 [CrossRef]
  29. Woo, T. H. S., Cheng, A. F., and Ling, J. M. (1992) BioTechniques 13, 696-698 [Medline] [Order article via Infotrieve]
  30. Higuchi, R. (1990) in PCR Protocols: A Guide to Methods and Applications (Innis, M. A., Gelfand, D. H., Sninsky, J. J., and White, T. J., eds), pp. 177-183, Academic Press, San Diego
  31. Amann, E., Ochs, B., and Abel, K.-J. (1988) Gene (Amst.) 69, 301-314 [CrossRef][Medline] [Order article via Infotrieve]
  32. Macnab, R. M. (1976) J. Clin. Microbiol. 4, 258-265 [Abstract/Free Full Text]
  33. Lanzetta, P. A., Alvarez, L. J., Reinach, P. S., and Candia, O. A. (1979) Anal. Biochem. 100, 95-97 [CrossRef][Medline] [Order article via Infotrieve]
  34. Vogel, G., and Steinhart, R. (1976) Biochemistry 15, 208-216 [CrossRef][Medline] [Order article via Infotrieve]
  35. Perczel, A., Park, K., and Fasman, G. D. (1992) Anal. Biochem. 203, 83-93 [CrossRef][Medline] [Order article via Infotrieve]
  36. Abrahams, J. P., Leslie, A. G. W., Lutter, R., and Walker, J. E. (1994) Nature (London) 370, 621-628 [CrossRef][Medline] [Order article via Infotrieve]
  37. Aizawa, S.-I. (1996) Mol. Microbiol. 19, 1-5 [CrossRef][Medline] [Order article via Infotrieve]
  38. Albertini, A. M., Caramori, T., Crabb, W. D., Scoffone, F., and Galizzi, A. (1991) J. Bacteriol. 173, 3573-3579 [Abstract/Free Full Text]
  39. Ge, Y., Old, I., Saint Girans, I., Yelton, D. B., and Charon, N. W. (1996) Gene (Amst.) 168, 73-75 [CrossRef][Medline] [Order article via Infotrieve]
  40. Ballado, T., Campos, A., Camarena, L., and Dreyfus, G. (1996) Gene (Amst.) 170, 69-72 [CrossRef][Medline] [Order article via Infotrieve]
  41. Goodfellow, I. G., Pollitt, C. E., and Sockett, R. E. (1996) FEMS Microbiol. Lett. 142, 111-116 [CrossRef][Medline] [Order article via Infotrieve]
  42. Slonczewski, J. L., Rosen, B. P., Alger, J. R., and Macnab, R. M. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 6271-6275 [Abstract/Free Full Text]
  43. Neuhard, J., and Nygaard, P. (1987) in Escherichia coli and Salmonella typhimurium: Cellular and Molecular Biology (Neidhardt, F. C., Ingraham, J. L., Low, K. B., Magasanik, B., Schaechter, M., and Umbarger, H. E., eds), Vol. 1, pp. 445-473, American Society for Microbiology, Washington, DC
  44. Lill, R., Cunningham, K., Brundage, L. A., Ito, K., Oliver, D., and Wickner, W. (1989) EMBO J. 8, 961-966 [Medline] [Order article via Infotrieve]
  45. Morbach, S., Tebbe, S., and Schneider, E. (1993) J. Biol. Chem. 268, 18617-18621 [Abstract/Free Full Text]
  46. Senior, A. E. (1990) Annu. Rev. Biophys. Biophys. Chem. 19, 7-41 [CrossRef][Medline] [Order article via Infotrieve]
  47. Walker, J. E., Saraste, M., Runswick, M. J., and Gay, N. J. (1982) EMBO J. 1, 945-951 [Medline] [Order article via Infotrieve]
  48. O'Brien, M. C., Flaherty, K. M., and McKay, D. B. (1996) J. Biol. Chem. 271, 15874-15878 [Abstract/Free Full Text]
  49. Parsonage, D., Wilke-Mounts, S., and Senior, A. E. (1987) J. Biol. Chem. 262, 8022-8026 [Abstract/Free Full Text]
  50. Koronakis, E., Hughes, C., Milisav, I., and Koronakis, V. (1995) Mol. Microbiol. 16, 87-96 [CrossRef][Medline] [Order article via Infotrieve]
  51. Walker, J. E., Fearnley, I. M., Gay, N. J., Gibson, B. W., Northrop, F. D., Powell, S. J., Runswick, M. J., Saraste, M., and Tybulewicz, V. L. J. (1985) J. Mol. Biol. 184, 677-701 [CrossRef][Medline] [Order article via Infotrieve]
  52. Cross, R. L., Cunningham, D., Miller, C. G., Xue, Z., Zhou, J.-M., and Boyer, P. D. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 5715-5719 [Abstract/Free Full Text]
  53. Wise, J. G. (1990) J. Biol. Chem. 265, 10403-10409 [Abstract/Free Full Text]
  54. Pedersen, P. L., and Carafoli, E. (1987) Trends Biochem. Sci. 12, 146-150 [CrossRef]
  55. Noumi, T., Maeda, M., and Futai, M. (1987) FEBS Lett. 213, 381-384 [CrossRef][Medline] [Order article via Infotrieve]
  56. Lee, R. S.-F., Pagan, J., Satre, M., Vignais, P. V., and Senior, A. E. (1989) FEBS Lett. 253, 269-272 [CrossRef][Medline] [Order article via Infotrieve]
  57. Weber, J., Lee, R. S. F., Grell, E., and Senior, A. E. (1992) Biochemistry 31, 5112-5116 [CrossRef][Medline] [Order article via Infotrieve]
  58. Wise, J. G., Latchney, L. R., Ferguson, A. M., and Senior, A. E. (1984) Biochemistry 23, 1426-1432 [CrossRef][Medline] [Order article via Infotrieve]
  59. Wise, J. G., Duncan, T. M., Latchney, L. R., Cox, D. N., and Senior, A. E. (1983) Biochem. J. 215, 343-350 [Medline] [Order article via Infotrieve]
  60. Palleros, D. R., Shi, L., Reid, K. L., and Fink, A. L. (1994) J. Biol. Chem. 269, 13107-13114 [Abstract/Free Full Text]
  61. Gao, B., Greene, L., and Eisenberg, E. (1994) Biochemistry 33, 2048-2054 [CrossRef][Medline] [Order article via Infotrieve]
  62. Palleros, D. R., Reid, K. L., Shi, L., Welch, W. J., and Fink, A. L. (1993) Nature 365, 664-666 [CrossRef][Medline] [Order article via Infotrieve]
  63. Schmid, D., Baici, A., Gehring, H., and Christen, P. (1994) Science 263, 971-973 [Abstract/Free Full Text]
  64. Satre, M., Lunardi, J., Pougeois, R., and Vignais, P. V. (1979) Biochemistry 18, 3134-3139 [CrossRef][Medline] [Order article via Infotrieve]
  65. Macara, I. G. (1980) Trends Biochem. Sci. 5, 92-95
  66. Bowman, E. J., Siebers, A., and Altendorf, K. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 7972-7976 [Abstract/Free Full Text]
  67. Bowman, B. J., and Bowman, E. J. (1986) J. Membr. Biol. 94, 83-97 [CrossRef][Medline] [Order article via Infotrieve]
  68. Takeda, K., Miki, J., Kanazawa, H., Tsuchiya, T., and Futai, M. (1985) J. Biochem. (Tokyo) 97, 1401-1407 [Abstract/Free Full Text]
  69. Oliver, D. B., Cabelli, R. J., Dolan, K. M., and Jarosik, G. P. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 8227-8231 [Abstract/Free Full Text]
  70. Cleland, W. W. (1979) Methods Enzymol. 63, 103-138 [Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg